1. Scrip
  2. >>R&D
  3. >>Clinical Trials

89bio’s FGF21 Analog May Offer Fibrosis Benefit In Cirrhotic NASH Patients

 
• By Joseph Haas

At AASLD, 89bio presented subgroup analysis from its successful Phase IIb NASH study indicating that the drug may meaningfully reduce fibrosis even in the sickest patients, those with cirrhosis.

Cirrhotic liver
89bio's pegozafermin shows fibrosis reduction in small subgroup of cirrhotic NASH patients • Source: Shutterstock

Perhaps already best positioned in the competitive FGF21 analog class in non-alcoholic steatohepatitis development, 89bio, Inc. bolstered its positioning with a late-breaker presentation on 12 November at the American Association for the Study of Liver Disease meeting with subgroup analysis from its successful Phase IIb study of pegozafermin showing that the weekly injectable drug might offer fibrosis benefit in the sickest patients, those with cirrhosis (F4 fibrosis).

Key Takeaways

  • 89bio presented Phase IIb subgroup analysis at the AASLD conference suggesting a fibrosis-reduction benefit for pegozafermin in cirrhotic NASH patients.

  • These data findings follow Akero data showing a numeric but not statistically significant reduction in fibrosis in cirrhotic patients with its efruxifermin, an FGF21 analog like the 89bio candidate

89bio is competing primarily with Akero Therapeutics, Inc. and its Phase II efruxifermin and privately held Boston Pharmaceuticals Inc. with its BOS-580 in the FGF21 class. 89bio reported successful data from the Phase IIb ENLIVEN study in March showing that pegozafermin could reduce fibrosis and resolve NASH in patients with F2 or F3 fibrosis scores

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.